Top Page
Zhong Ji Longevity Science Group Limited
(0767)
Zhong Ji Longevity Science Group Limited (0767) vs. iShares MSCI Hong Kong ETF (EWH)
Zhong Ji Longevity Science Group Limited Business Overview & Revenue Model
Zhong Ji Longevity Science Group Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 174.06M | 168.63M | 64.99M | 89.44M | 62.98M | 81.41M |
| Gross Profit | 174.06M | 57.41M | 56.28M | 79.41M | 49.40M | 71.83M |
| EBITDA | -17.56M | -29.96M | 13.02M | 15.99M | 16.13M | -11.89M |
| Net Income | -46.43M | -34.73M | 2.31M | -904.00K | 6.05M | -11.49M |
Balance Sheet | ||||||
| Total Assets | 509.39M | 525.63M | 509.25M | 484.84M | 517.50M | 478.24M |
| Cash, Cash Equivalents and Short-Term Investments | 30.04M | 47.84M | 81.08M | 60.07M | 19.44M | 40.80M |
| Total Debt | 12.77M | 19.11M | 20.20M | 11.76M | 12.93M | 8.70M |
| Total Liabilities | 77.85M | 125.49M | 78.79M | 63.99M | 46.78M | 23.35M |
| Stockholders Equity | 404.98M | 373.42M | 403.40M | 393.83M | 443.75M | 428.83M |
Cash Flow | ||||||
| Free Cash Flow | -106.77M | -61.76M | 15.28M | 11.08M | -40.51M | -192.89M |
| Operating Cash Flow | -104.97M | -61.05M | 15.28M | 12.11M | -39.62M | -191.54M |
| Investing Cash Flow | 10.45M | 11.47M | 382.00K | 16.59M | 2.91M | 70.11M |
| Financing Cash Flow | 20.18M | 15.17M | 6.02M | -7.45M | 3.44M | -1.43M |
Zhong Ji Longevity Science Group Limited Technical Analysis
Zhong Ji Longevity Science Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$332.00M | 6.86 | 5.24% | 5.56% | -1.47% | 2.86% | |
68 Neutral | HK$348.10M | 6.53 | 2.48% | 4.71% | -25.70% | -39.65% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
58 Neutral | HK$334.80M | 11.51 | 1.12% | ― | -9.75% | -81.16% | |
53 Neutral | HK$228.63M | 7.60 | 4.83% | ― | -25.74% | ― | |
46 Neutral | HK$331.06M | ― | -11.40% | ― | 121.54% | -8360.00% |
Zhong Ji Longevity Science Group Limited Corporate Events
Zhong Ji Longevity Science Group Limited has announced its upcoming annual general meeting scheduled for June 27, 2025, in Hong Kong. The meeting will address several key resolutions including the re-election of directors, re-appointment of auditors, and authorization for the board to manage share allotments. This meeting is significant as it will influence the company’s governance and financial strategies, impacting stakeholders and potentially affecting the company’s market positioning.
Zhong Ji Longevity Science Group Limited faced a legal challenge when the Department of Health, through the Office for Regulation of Private Healthcare Facilities, canceled its Day Procedure Centre License due to allegations of using unlicensed equipment and handling unregistered pharmaceutical products. Despite being acquitted of these allegations, the company suffered reputational damage and financial losses, as it had to vacate its premises and write off significant capital investments.
Zhong Ji Longevity Science Group Limited has announced the formation of a joint venture with Hua Li Life Sciences Technology Company Limited in China. The joint venture, owned 51% by Zhong Ji Health and 49% by Hua Li Life, will focus on providing longevity health services in China, with an initial registered capital of RMB1,000,000. This collaboration aims to leverage Hua Li Life’s expertise in life sciences and conference organization to enhance Zhong Ji’s market presence in the promising health longevity science sector, catering to the increasing demand from wealthy clients for health and immunity improvement solutions.
Zhong Ji Longevity Science Group Limited announced its annual results for the year ended 31 December 2024, reporting a significant revenue increase of approximately 155.4% to HK$166.2 million compared to the previous year. Despite the revenue growth, the company experienced a net loss after tax of approximately HK$34.8 million, a decline from the net profit of HK$2.5 million in 2023, and decided not to recommend a final dividend for the year.
Zhong Ji Longevity Science Group Limited has issued a profit warning for the fiscal year ending December 31, 2024, anticipating a net loss between HK$32 million and HK$35 million, a significant decline from the previous year’s profit. This downturn is attributed to one-off legal and service fees related to loan recovery, substantial marketing costs for MNM supplements, and restructuring costs associated with the removal of the retail sales division and enhancement of service and product lines.
Zhong Ji Longevity Science Group Limited has announced a board meeting scheduled for March 28, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the payment of a final dividend and address other business matters, potentially impacting the company’s financial strategies and shareholder returns.
Zhong Ji Longevity Science Group Limited has entered into a strategic cooperation framework agreement with Super Fire (Xiamen) Technology Co., Ltd., leveraging mutual strengths to explore new business areas and enhance their longevity science and AI applications. This collaboration is expected to expand the company’s market share and contribute to sustainable revenue growth through joint development efforts and strategic distribution of health products.